𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Inhibition of human breast cancer xenograft growth by cruciferous vegetable constituent benzyl isothiocyanate

✍ Scribed by Renaud Warin; Dong Xiao; Julie A. Arlotti; Ajay Bommareddy; Shivendra V. Singh

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
273 KB
Volume
49
Category
Article
ISSN
0899-1987

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Benzyl isothiocyanate (BITC), a constituent of cruciferous vegetables such as garden cress, inhibits growth of human breast cancer cell lines in culture. The present study was undertaken to determine in vivo efficacy of BITC against MDA‐MB‐231 human breast cancer xenografts. The BITC administration retarded growth of MDA‐MB‐231 cells subcutaneously implanted in female nude mice without causing weight loss or any other side effects. The BITC‐mediated suppression of MDA‐MB‐231 xenograft growth correlated with reduced cell proliferation as revealed by immunohistochemical analysis for Ki‐67 expression. Analysis of the vasculature in the tumors from BITC‐treated mice indicated smaller vessel area compared with control tumors based on immunohistochemistry for angiogenesis marker CD31. The BITC‐mediated inhibition of angiogenesis in vivo correlated with downregulation of vascular endothelial growth factor (VEGF) receptor 2 protein levels in the tumor. Consistent with these results, BITC treatment suppressed VEGF secretion and VEGF receptor 2 protein levels in cultured MDA‐MB‐231 cells. Moreover, the BITC‐treated MDA‐MB‐231 cells exhibited reduced capacity for migration compared with vehicle‐treated control cells. In contrast to cellular data, BITC administration failed to elicit apoptotic response as judged by terminal deoxynucleotidyl transferase‐mediated dUTP nick‐end labeling assay. In conclusion, the present study demonstrates in vivo anti‐cancer efficacy of BITC against MDA‐MB‐231 xenografts in association with reduced cell proliferation and suppression of neovascularization. These preclinical observations merit clinical investigation to determine efficacy of BITC against human breast cancers. © 2010 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Growth inhibition of human gastrointesti
Growth inhibition of human gastrointestinal cancer xenograft lines by treatment with CPT-11 and VP-16
✍ Dr. Satoshi Nagai; Masaji Yamauchi; Tetsuya Satta; Yasuhiro Kodera; Ken Kondou; 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 316 KB

A water-soluble and stable camptothecin derivative, CPT-I 1, was found to possess a strong antitumor activity against various murine tumors. In the present study, CPT-I 1 was tested against ten human gastrointestinal cancer xenograft lines carried by nude mice. CPT-11 was very effective against nine

Inhibition of angiogenesis and breast ca
Inhibition of angiogenesis and breast cancer xenograft tumor growth by vegi, a novel cytokine of the tnf superfamily
✍ Yifan Zhai; Jingyi Yu; Luisa Iruela-Arispe; Wei-Qun Huang; Zheng Wang; Andrew J. 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 122 KB 👁 1 views

Recently, we reported a novel protein of the tumor necrosis factor (TNF) superfamily, named vascular endothelial cell growth inhibitor (VEGI), which is expressed predominantly in endothelial cells. When a secreted form of this new protein was overexpressed in mouse colon cancer cells, the growth of

Inhibition of tumor growth by biodegrada
Inhibition of tumor growth by biodegradable microspheres containing all-trans-retinoic acid in a human head-and-neck cancer xenograft
✍ Yongdoo Choi; Sang Yoon Kim; Sun Hee Kim; Jehoon Yang; Kyeongsoon Park; Youngro 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 149 KB

## Abstract Retinoids play essential roles in the regulation of cell differentiation and in the proliferation of various epithelial tissues, and atRA is one such active metabolite of retinoids. However, despite the known functions of atRA, its clinical applications are limited due to the induced me

Inhibition of growth of MX-1, MCF-7-MIII
Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238
✍ Zsuzsanna Kahán; Attila Nagy; Andrew V. Schally; Francine Hebert; Baodong Sun; K 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 158 KB 👁 1 views

Since somatostatin (sst) receptors are expressed in a high percentage of human breast cancers, we studied the effects of a targeted cytotoxic somatostatin analog (AN-238) formed by linking the highly active doxorubicin (DOX) derivative 2-pyrrolino-DOX (AN-201) to octapeptide RC-121 (D-Phe-Cys-Tyr-D-